Search Clinical Trials
Thank you for your interest in Vanderbilt research! Taking part in research is one way to be part of tomorrow’s health care discoveries. Vanderbilt is always looking for volunteers just like you so that our researchers can better understand how to prevent, diagnose, and treat diseases. Everyone is needed. Both healthy volunteers and people with health conditions can help us answer important questions that impact the health of our communities. Ready to start searching for a study?
- Enter a health condition or leave it blank if you are looking to join any study as a healthy volunteer.
- Enter your gender and age.
- Click View Results.
- Click on the study titles for information.
- Click on Contact/Details tab to get information for contacting the study team.
Condition of Interest |
---|
Comparison of Chemotherapy Before and After Surgery Versus After Surgery Alone for the Treatment of1
Stage II Gallbladder Cancer AJCC v8
Stage IIA Gallbladder Cancer AJCC v8
Stage IIB Gallbladder Cancer AJCC v8
Stage III Gallbladder Cancer AJCC v8
Stage IIIA Gallbladder Cancer AJCC v8
This phase II/III trial compares the effect of adding chemotherapy before and after
surgery versus after surgery alone (usual treatment) in treating patients with stage
II-III gallbladder cancer. Chemotherapy drugs, such as gemcitabine and cisplatin, work in
different ways to stop the growth of tum1 expand
This phase II/III trial compares the effect of adding chemotherapy before and after surgery versus after surgery alone (usual treatment) in treating patients with stage II-III gallbladder cancer. Chemotherapy drugs, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before surgery may make the tumor smaller; therefore, may reduce the extent of surgery. Additionally, it may make it easier for the surgeon to distinguish between normal and cancerous tissue. Giving chemotherapy after surgery may kill any remaining tumor cells. This study will determine whether giving chemotherapy before surgery increases the length of time before the cancer may return and whether it will increase a patient's life span compared to the usual approach. Type: Interventional Start Date: Feb 2021 |
Cholinergic Health After Menopause (CHAMP)
Postmenopausal Symptoms
Aging
Alzheimer Disease
Women are at increased risk for Alzheimer's disease (AD). Notably at menopause, some
women experience a change in cognition. However, not all women experience negative
effects of menopause on cognition. The cognitive changes that occur at menopause have not
yet been connected to late life risk for1 expand
Women are at increased risk for Alzheimer's disease (AD). Notably at menopause, some women experience a change in cognition. However, not all women experience negative effects of menopause on cognition. The cognitive changes that occur at menopause have not yet been connected to late life risk for pathological aging including AD. Thus, understanding the neurobiological factors related to individual differences in cognition at menopause is critical for understanding normal cognitive aging and for determining risk for pathological aging. The challenge in understanding the role of estrogen loss on the risk for AD is the long lag time between the hormonal changes at menopause and the clinical manifestations of AD. Thus, identifying how the hormone changes after menopause are related to AD risk will alter the risk calculus for postmenopausal women in the future. The novel study proposed here will examine an established AD-related neurotransmitter-based mechanism that may also underlie cognitive changes after menopause. The investigators propose that the change in the hormonal milieu at menopause interacts with the cholinergic system and other brain pathologies to influence a woman's risk for cognitive decline. Preclinical studies have shown that estrogen is necessary for normal cholinergic functioning and its withdrawal leads to cholinergic dysfunction and cognitive impairment. It is important to determine whether menopause-related cognitive changes correlate with both cholinergic functional integrity and established AD biomarkers that portend increased risk for late-life cognitive impairment or dementia. This study will examine brain functioning following cholinergic blockade to separate individuals into those who are able to compensate for the hormone change after menopause and those who are not. The investigators hypothesize women with poor compensation have increased sensitivity to cholinergic blockade by showing poor performance on a cognitive task, altered brain activation, and decreased basal forebrain cholinergic system (BFCS) volume. These cholinergic markers will be related to menopausal factors associated with poor cognition and biomarkers of AD. Specific Aim 1 is to examine cholinergic functional "integrity" by measuring working memory performance, functional brain activation, and BFCS structure in postmenopausal women. Specific Aim 2 will examine whether individual differences in menopause-relevant symptoms and known AD biomarkers are related to cognition and brain activation after anticholinergic challenge. The public health significance of this study is that it will identify individual difference factors that are associated with cognitive performance changes after menopause and their relationship to structural, functional, and biomarker evidence of risk for later life cognitive dysfunction. Knowledge of these factors will serve to advance personalized future risk-mitigation strategies for women including hormonal, medication, cognitive remediation, etc. that will be the subject of further research. Type: Interventional Start Date: Mar 2020 |
Chest Drain Regular Flushing in Complicated Parapneumonic Effusions and Empyemas
Empyema, Pleural
Pleural Infection
Infections of the pleural space are common, and patients require antibiotics and chest
drain placement to evacuate the chest from the infected fluid. Chest drains can get
blocked by the drainage fluid and material. For this reason, it is thought that flushing
the chest drain with saline solution, c1 expand
Infections of the pleural space are common, and patients require antibiotics and chest drain placement to evacuate the chest from the infected fluid. Chest drains can get blocked by the drainage fluid and material. For this reason, it is thought that flushing the chest drain with saline solution, can help maintain the patency of the tube. This proposed study will evaluate the impact of regular chest drain flushing on the length of time to chest tube removal and total hospitalization as well as improvement in chest imaging and the need for additional interventions on the infected space. Type: Interventional Start Date: Jun 2024 |
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other So1
Clear Cell Renal Cell Carcinoma
Solid Tumors
The purpose of this study is to evaluate the safety and tolerability of:
- casdatifan when taken alone in participants with advanced solid tumor malignancies
and clear cell renal cell carcinoma (ccRCC) during the dose escalation stage; and
- casdatifan monotherapy and casdatifan in com1 expand
The purpose of this study is to evaluate the safety and tolerability of: - casdatifan when taken alone in participants with advanced solid tumor malignancies and clear cell renal cell carcinoma (ccRCC) during the dose escalation stage; and - casdatifan monotherapy and casdatifan in combination with cabozantinib or zimberelimab in participants with ccRCC in the dose expansion stage Type: Interventional Start Date: Oct 2022 |
ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2
Ulcerative Colitis
This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and
safety of ABX464 given at 25 or 50 mg QD in inducing clinical remission in subjects with
moderately to severely active ulcerative colitis who have inadequate response, no
response, a loss of response, or an int1 expand
This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464 given at 25 or 50 mg QD in inducing clinical remission in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies [corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)] and/or advanced therapies [biologics (TNF inhibitors, anti-integrins, anti-IL-23), and/or S1P receptor modulators, and/or JAK inhibitors]. Type: Interventional Start Date: Dec 2022 |
Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC1
Advanced Clear Cell Renal Cell Carcinoma
Metastatic Clear Cell Renal Cell Carcinoma
Stage III Renal Cell Cancer AJCC v8
Stage IV Renal Cell Cancer AJCC v8
This phase II trial tests whether using genetic testing of tumor tissue to select the
optimal treatment regimen works in treating patients with clear cell renal cell (kidney)
cancer that has spread to other places in the body (advanced or metastatic). The current
Food and Drug Administration (FDA)-1 expand
This phase II trial tests whether using genetic testing of tumor tissue to select the optimal treatment regimen works in treating patients with clear cell renal cell (kidney) cancer that has spread to other places in the body (advanced or metastatic). The current Food and Drug Administration (FDA)-approved regimens for advanced kidney cancer fall into two categories. One treatment combination includes two immunotherapy drugs (nivolumab plus ipilimumab), which are delivered by separate intravenous infusions into a vein. The other combination is one immunotherapy drug (nivolumab infusion) plus an oral pill taken by mouth (cabozantinib). Nivolumab and ipilimumab are "immunotherapies" which release the brakes of the immune system, thus allowing the patient's own immune system to better kill cancer cells. Cabozantinib is a "targeted therapy" specifically designed to block certain biological mechanisms needed for growth of cancer cells. In kidney cancer, cabozantinib blocks a tumor's blood supply. The genetic (DNA) makeup of the tumor may affect how well it responds to therapy. Testing the makeup (genes) of the tumor, may help match a treatment (from one of the above two treatment options) to the specific cancer and increase the chance that the disease will respond to treatment. The purpose of this study is to learn if genetic testing of tumor tissue may help doctors select the optimal treatment regimen to which advanced kidney cancer is more likely to respond. Type: Interventional Start Date: Dec 2022 |
Enhanced Recovery After Surgery in Extremity Sarcoma
Sarcoma
The purpose of this study is to demonstrate the efficacy of implementing the enhanced
recovery after surgery (ERAS) pathway in a prospective manner to patients undergoing
surgical treatment for extremity sarcoma. expand
The purpose of this study is to demonstrate the efficacy of implementing the enhanced recovery after surgery (ERAS) pathway in a prospective manner to patients undergoing surgical treatment for extremity sarcoma. Type: Interventional Start Date: Dec 2020 |
Registry of Avance® Nerve Graft's Utilization and Recovery Outcomes Post Peripheral Nerve Reconstru1
Peripheral Nerve Injuries
This study is a registry of general use of Avance Nerve Graft and is intended to evaluate
the uses, response rates, and safety of Avance Nerve Graft in the real-life clinical
setting. Optional addendums 1 and 2 included in the protocol are intended to establish
comparative groups and focused subgro1 expand
This study is a registry of general use of Avance Nerve Graft and is intended to evaluate the uses, response rates, and safety of Avance Nerve Graft in the real-life clinical setting. Optional addendums 1 and 2 included in the protocol are intended to establish comparative groups and focused subgroups within the registry. Type: Observational Start Date: Nov 2008 |
Home-Based Cardiac Rehabilitation Using a Novel Mobile Health Exercise Regimen Following Transcathe1
Valvular Heart Disease
The vast majority of cardiac rehabilitation eligible individuals do not participate in
center based cardiac rehabilitation (CBCR). While steps to encourage participation in
CBCR are important, many individuals will still not participate for a variety of reasons.
This randomized controlled trial is1 expand
The vast majority of cardiac rehabilitation eligible individuals do not participate in center based cardiac rehabilitation (CBCR). While steps to encourage participation in CBCR are important, many individuals will still not participate for a variety of reasons. This randomized controlled trial is evaluating a home-based cardiac rehabilitation (HBCR) intervention delivered using a custom app and digital tools in patients undergoing transcatheter heart valve interventions (THVIs). After a brief roll-in period, participants not intending to participate in CBCR are randomized to one of three groups: (1) control, (2) HBCR mobile health intervention with hands-off delivery, and (3) HBCR mobile health intervention with interactive delivery. Participants in the intervention groups (hands-off/interactive delivery) will also be randomized to continue the intervention for 12 weeks or 24 weeks. The intervention targets key health behaviors and includes traditional cardiac rehabilitation components. The study will assess the effect of the intervention on clinical events, physical activity, quality of life, and other outcomes. Those who intend to participate in CBCR will be followed in a registry. Type: Interventional Start Date: Dec 2023 |
SGC Stimulation, Perioperative Vascular Reactivity, and Organ Injury in Cardiac Surgery
Endothelial Dysfunction
Vascular Diseases
Kidney Injury
Brain Disease
Vascular Inflammation
The goal of this mechanistic clinical trial is to learn about the effects of medications
called soluble guanylyl cyclase stimulators on vascular function and markers of kidney
and brain injury in patients having heart surgery. The main questions it aims to answer
are:
1. Does soluble guanylyl cy1 expand
The goal of this mechanistic clinical trial is to learn about the effects of medications called soluble guanylyl cyclase stimulators on vascular function and markers of kidney and brain injury in patients having heart surgery. The main questions it aims to answer are: 1. Does soluble guanylyl cyclase stimulation improve blood vessel function compared to placebo? 2. Does soluble guanylyl cyclase stimulation decrease markers of kidney injury and brain injury compared to placebo? Participants will be randomized to a soluble guanylyl cyclase stimulator called vericiguat or placebo, and researchers will compare vascular function and markers of brain and kidney injury to see if vericiguat improves vascular function and reduces markers of injury. This will provide important information to determine the underlying reasons that patients have some kidney and brain function problems after having heart surgery. Type: Interventional Start Date: May 2023 |
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the1
Plasma Cell Myeloma
RISS Stage I Plasma Cell Myeloma
RISS Stage II Plasma Cell Myeloma
This phase III trial compares the combination of four drugs (daratumumab, bortezomib,
lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab,
lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by
blocking some of the enzymes needed for cell1 expand
This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Anti-inflammatory drugs, such as dexamethasone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Adding bortezomib to daratumumab, lenalidomide, and dexamethasone may be more effective in shrinking the cancer or preventing it from returning, compared to continuing on daratumumab, lenalidomide, and dexamethasone. Type: Interventional Start Date: Feb 2021 |
Study on Basal Joint Arthritis Prospective
Osteoarthrosis of the Carpometacarpal Joint of the Thumb
The data in this prospective registry will be used 1) to define which surgical and
nonoperative techniques are most effective at providing pain relief, restoring function,
are cost effective, and patients are satisfied with their outcomes; and 2) to design
focused clinical questions regarding the o1 expand
The data in this prospective registry will be used 1) to define which surgical and nonoperative techniques are most effective at providing pain relief, restoring function, are cost effective, and patients are satisfied with their outcomes; and 2) to design focused clinical questions regarding the optimal treatment of basal joint arthritis of the thumb in future randomized controlled trials. There are no interventions or changes in patient care associated with this study. Type: Observational Start Date: Mar 2007 |
Right Ventricle Lipid in Pulmonary Arterial Hypertension (PAH)
Idiopathic Pulmonary Arterial Hypertension
Heritable Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension Associated With Connective Tissue Disease
The investigators propose to study the relationship between right ventricle (RV)
steatosis and RV function, exercise capacity, and outcomes in humans with pulmonary
arterial hypertension (PAH) and to identify potential drivers of lipid accumulation. expand
The investigators propose to study the relationship between right ventricle (RV) steatosis and RV function, exercise capacity, and outcomes in humans with pulmonary arterial hypertension (PAH) and to identify potential drivers of lipid accumulation. Type: Observational Start Date: Jan 2023 |
Nasotracheal Intubation With VL vs DL in Infants Trial
Intubation Complication
Intubation; Difficult or Failed
Hypoxia
Hypoxemia
Anesthesia Intubation Complication
Nasotracheal Intubation with Videolaryngoscopy versus Direct Laryngoscopy in Infants
(NasoVISI) Trial is a prospective randomized multicenter study. The study will be
conducted at 8 centers in the United States. It is expected that approximately 700
subjects enrolled to product 670 evaluable subjec1 expand
Nasotracheal Intubation with Videolaryngoscopy versus Direct Laryngoscopy in Infants (NasoVISI) Trial is a prospective randomized multicenter study. The study will be conducted at 8 centers in the United States. It is expected that approximately 700 subjects enrolled to product 670 evaluable subjects.The randomization is 1:1 naso tracheal intubation with the Storz C-Mac Video Videolaryngoscopy (VL) or the Standard Direct Laryngoscope (DL). The primary objective is to compare the nasotracheal intubation (NTI) first attempt success rate using VL vs. DL in infants 0-365 days of age presenting for cardiothoracic surgery and cardiac catheterizations. Type: Interventional Start Date: Jun 2022 |
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Ly1
Lymphoma, Non-Hodgkin
Relapsed Non Hodgkin Lymphoma
Refractory B-Cell Non-Hodgkin Lymphoma
Non Hodgkin Lymphoma
Lymphoma
CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and
immunogenicity of CB-010 in adults with relapsed/refractory B cell non-Hodgkin lymphoma
after lymphodepletion consisting of cyclophosphamide and fludarabine. expand
CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and immunogenicity of CB-010 in adults with relapsed/refractory B cell non-Hodgkin lymphoma after lymphodepletion consisting of cyclophosphamide and fludarabine. Type: Interventional Start Date: May 2021 |
Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BL1
AVB - Atrioventricular Block
Fetal AVB
Fetal complete (i.e., third degree, 3°) atrioventricular block (AVB), identified in the
2nd trimester of pregnancy in an otherwise normally developing heart, is almost
universally associated with maternal anti-Ro autoantibodies and results in death in a
fifth of cases. To date treatment of 3° AVB h1 expand
Fetal complete (i.e., third degree, 3°) atrioventricular block (AVB), identified in the 2nd trimester of pregnancy in an otherwise normally developing heart, is almost universally associated with maternal anti-Ro autoantibodies and results in death in a fifth of cases. To date treatment of 3° AVB has been ineffective in restoring normal rhythm (NR) which may be because current surveillance is limited to once- weekly fetal echocardiograms. It is hypothesized that there may be a vital transition period of several hours in which incomplete block (2° AVB) may be successfully treated avoiding fully advanced irreversible 3° AVB. To optimize the likelihood of timely detection of the transition period this study comprises three steps: 1) to risk stratify for high titer anti-Ro antibodies, which are necessary but not sufficient to develop fetal AVB; 2) to empower mothers to identify 2° AVB by using fetal heart rate and rhythm monitoring (FHRM) at home, and 3) to rapidly treat mothers who detect an abnormality by monitoring with an urgent echocardiogram that confirms 2° AVB with the hope of reversing 2° AVB before it becomes permanent (3° AVB). In addition, it will be determined if FHRM reduces the need for weekly echoes. Although mothers with low titer anti-Ro will not be continued in Step 2 and therefore not followed by FHRM, birth ECGs will be collected to confirm that low titer antibodies do not confer risk. It is anticipated that this study will provide an evidenced based surveillance strategy for those mothers at high risk of having a child with 3° AVB. Type: Interventional Start Date: Aug 2020 |
VZV in the Enteric Nervous System: Pathogenesis and Consequences
Achalasia
Varicella zoster virus (VZV) is the cause of chickenpox and shingles, but it also
infects, becomes latent, and reactivates in nerve cells of the bowel to cause a
gastrointestinal disorder ("enteric shingles"). The Investigators recently found that a
chronic active VZV infection, a form of enteric s1 expand
Varicella zoster virus (VZV) is the cause of chickenpox and shingles, but it also infects, becomes latent, and reactivates in nerve cells of the bowel to cause a gastrointestinal disorder ("enteric shingles"). The Investigators recently found that a chronic active VZV infection, a form of enteric shingles, is associated with achalasia, a severe disease in which the passage of food from esophagus to stomach is impaired. We now propose to eradicate VZV to determine whether its association with achalasia is causal, to identify the genetic basis behind VZV reactivation in the esophagus, and the relationship of mast cells to enteric shingles and abdominal pain. Type: Interventional Start Date: Mar 2023 |
Preserving Fertility After Colorectal Cancer Study
Colorectal Cancer
The PREFACE Study is a prospective, longitudinal cohort study of reproductive health and
clinical outcomes among individuals diagnosed with colorectal cancer between age 18 to 49
years. expand
The PREFACE Study is a prospective, longitudinal cohort study of reproductive health and clinical outcomes among individuals diagnosed with colorectal cancer between age 18 to 49 years. Type: Observational Start Date: Dec 2021 |
COgnitive and Physical Exercise to Improve Outcomes After Surgery (COPE-iOS) Study
Cognitive Impairment
Disability Physical
Surgery
The COgnitive and Physical Exercise to improve Outcomes after Surgery (COPE-iOS) study is
testing the hypothesis that a pragmatic program combining computerized cognitive training
and physical training throughout the perioperative period will improve long-term
cognitive and disability outcomes in o1 expand
The COgnitive and Physical Exercise to improve Outcomes after Surgery (COPE-iOS) study is testing the hypothesis that a pragmatic program combining computerized cognitive training and physical training throughout the perioperative period will improve long-term cognitive and disability outcomes in older surgical patients at high risk for decline. To accomplish these goals, the Investigators are randomizing 250 patients ≥60 years old undergoing elective major non-cardiac surgery with expected hospitalization ≥3 days to a pragmatic comprehensive training program (computerized cognitive training and supervised progressive physical exercise) or to active control (control computer game, stretching exercises) for 2-4 weeks prior to surgery and for 3 months after discharge. At baseline and after discharge, the Investigators will assess global cognition, activities of daily living, depression, endothelial and blood brain barrier function (blood biomarkers), and neuroimaging (anatomical and functional MRI). In this early stage trial, the Investigators will determine if certain subgroups benefit most, program aspects with greatest effect on outcomes, mechanistic associations with outcomes, and additional exploratory analyses. Type: Interventional Start Date: Oct 2021 |
Reducing Reintubation Risk in High-Risk Cardiac Surgery Patients With High-Flow Nasal Cannula
Intubation
Cardiovascular Surgical Procedure
The purpose of this study is to compare reintubation rates and outcomes of patients
treated with high-flow nasal canula oxygen therapy (HFNC) and patients treated with
provider choice of standard care. expand
The purpose of this study is to compare reintubation rates and outcomes of patients treated with high-flow nasal canula oxygen therapy (HFNC) and patients treated with provider choice of standard care. Type: Interventional Start Date: Nov 2021 |
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
Advanced Malignant Neoplasm
Acute Myeloid Leukemia
Mixed Lineage Leukemia
Mixed Lineage Acute Leukemia
Acute Leukemia of Ambiguous Lineage
This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess
ziftomenib, a menin-MLL(KMT2A) inhibitor, in patients with relapsed or refractory acute
myeloid leukemia (AML) as part of Phase 1. In Phase 2, assessment of ziftomenib will
continue in patients with NPM1-m AML. expand
This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess ziftomenib, a menin-MLL(KMT2A) inhibitor, in patients with relapsed or refractory acute myeloid leukemia (AML) as part of Phase 1. In Phase 2, assessment of ziftomenib will continue in patients with NPM1-m AML. Type: Interventional Start Date: Sep 2019 |
Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell1
Recurrent Lung Non-Small Cell Carcinoma
Stage IV Lung Cancer AJCC v8
This phase III trial compares the effect of the combination of ramucirumab and
pembrolizumab versus standard of care chemotherapy for the treatment of non-small cell
lung cancer that is stage IV or that has come back after a period of improvement
(recurrent). Ramucirumab is a monoclonal antibody th1 expand
This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment of non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help doctors find out if giving ramucirumab with pembrolizumab is more effective at treating patients with stage IV or recurrent non-small cell lung cancer than standard chemotherapy. Type: Interventional Start Date: Mar 2023 |
Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neur1
Neurodegenerative Diseases
Parkinson Disease
Parkinson Disease Psychosis
It is hypothesize that patients with clinically diagnosed neurodegenerative diseases will
have significantly different receptor occupancy of 5HT2A receptors compared to a healthy
age/sex-matched control group. This will be tested by measuring 5HT2A receptor density
using the PET radioligand (R)-[181 expand
It is hypothesize that patients with clinically diagnosed neurodegenerative diseases will have significantly different receptor occupancy of 5HT2A receptors compared to a healthy age/sex-matched control group. This will be tested by measuring 5HT2A receptor density using the PET radioligand (R)-[18F]MH.MZ in both populations. Type: Interventional Start Date: Jan 2023 |
Improving Care After Inherited Cancer Testing
Inherited Cancer Syndrome
Prostate Cancer
Colorectal Cancer
Endometrial Cancer
Breast Cancer
The IMPACT Study seeks to refine and evaluate the effectiveness of interventions on
improving guideline-adherent cancer risk management (CRM) and family communication (FC)
of genetic test results for individuals with a documented pathogenic/likely pathogenic
(P/LP) variant, and FC of family cancer1 expand
The IMPACT Study seeks to refine and evaluate the effectiveness of interventions on improving guideline-adherent cancer risk management (CRM) and family communication (FC) of genetic test results for individuals with a documented pathogenic/likely pathogenic (P/LP) variant, and FC of family cancer history for individuals with a variant of uncertain significance (VUS) in an inherited cancer gene. Type: Interventional Start Date: Aug 2022 |
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Exte1
NASH - Nonalcoholic Steatohepatitis
This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver
fibrosis histological stage F2 or F3 expand
This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3 Type: Interventional Start Date: Aug 2021 |
- Previous
- Next